NCT06194825 - EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

May 14, 2026

Study Completion Date

January 5, 2027

Conditions

Transthyretin Amyloid Cardiomyopathy

Interventions

DRUG

Eplontersen

Eplontersen by subcutaneous injection

DRUG

Placebo

Eplontersen-matching placebo by subcutaneous injection

Trial Locations (26)

100029

Research Site, Beijing

100034

Research Site, Beijing

100037

Research Site, Beijing

100191

Research Site, Beijing

100730

Research Site, Beijing

150001

Research Site, Ha’erbin

200032

Research Site, Shanghai

215006

Research Site, Suzhou

250001

Research Site, Jinan

310003

Research Site, Hangzhou

310014

Research Site, Hangzhou

310052

Research Site, Hangzhou

330006

Research Site, Nanchang

400010

Research Site, Chongqing

400042

Research Site, Chongqing

410008

Research Site, Changsha

410013

Research Site, Changsha

430030

Research Site, Wuhan

430033

Research Site, Changsha

430060

Research Site, Wuhan

510062

Research Site, Guangzhou

510100

Research Site, Guangzhou

610041

Research Site, Chengdu

610072

Research Site, Chengdu

710061

Research Site, Xi'an

030001

Research Site, Taiyuan